Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

GPI 15715 For Sedation in the Intensive Care Unit (ICU) Setting

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00125398
Recruitment Status : Completed
First Posted : August 1, 2005
Last Update Posted : November 7, 2008
Sponsor:
Information provided by:
Eisai Inc.

Brief Summary:
Patients who are in the intensive care unit after surgery and require mechanical breathing support (intubation and ventilation) usually require sedation to avoid agitation and excessive stress responses. Short-acting sedatives such as midazolam and propofol are the drugs typically used for this. Propofol provides for fast sedation and fast recovery from sedation. Midazolam is slower to sedation and slower for recovery, but may provide some advantages over propofol, such as a lower incidence of hypotension (low blood pressure). This study will look at propofol compared to a product with fast sedation and recovery like that of propofol but with less of a chance for hypotension like with midazolam. Patients will be treated with the product for up to 8 hours and then will be monitored for 8 hours following treatment.

Condition or disease Intervention/treatment Phase
Postoperative Sedation Intubation Respiration, Artificial Drug: AQUAVAN (fospropofol disodium; GPI 15715 ) Phase 2

Detailed Description:

Patients who are intubated and ventilated and will require up to 8 hours of sedation in the ICU are eligible for participation in this study. Patients will be randomized to receive 1 of 3 treatments. One treatment is standard of care, a propofol infusion. The other two treatment arms are infusions of GPI 15715 (AQUAVAN), one with a bolus and one without.

Patients will be treated for up to 8 hours and monitored for eight hours post treatment. If there are signs of agitation during the up to 8 hour treatment period, the infusion of the sedative medicine will be increased according to protocol.

Blood samples will be obtained periodically during the course of the study for safety evaluation and pharmacokinetic assessments. When the patient is ready for extubation or the end of the 8 hour study period has been reached, the infusion of the sedative agent will be discontinued and the patient will be monitored for 8 hours post treatment.

Guilford Pharmaceuticals was acquired by MGI PHARMA on October 3, 2005.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II, Randomized, Open-Label Study to Examine the Safety and Efficacy of GPI 15715 for Sedation of Patients Requiring Intubation and Mechanical Ventilation in the Intensive Care Unit Setting
Study Start Date : July 2005
Actual Study Completion Date : May 2007



Primary Outcome Measures :
  1. Safety and tolerability of infusions

Secondary Outcome Measures :
  1. Percentage of patients requiring rescue medications
  2. Evaluation of the onset of effect
  3. Evaluation of satisfaction with sedation
  4. Determination of pharmacokinetic (PK) levels of GPI 15715 in blood


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Require 2 to 8 hours of intubation and mechanical ventilation following elective surgery
  2. American Society of Anesthesiologists (ASA) status of I-IV

Exclusion Criteria:

  1. Requires emergency agency
  2. Requires neuromuscular blockers during sedation
  3. Requires use of epidural drug administration during sedation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00125398


Locations
Show Show 17 study locations
Sponsors and Collaborators
Eisai Inc.
Investigators
Layout table for investigator information
Study Director: James Jones, MD, PharmD Eisai Inc.
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00125398    
Other Study ID Numbers: 3000-0413
GPI 3000-0413
Sedation in an ICU Setting
First Posted: August 1, 2005    Key Record Dates
Last Update Posted: November 7, 2008
Last Verified: November 2008
Keywords provided by Eisai Inc.:
AQUAVAN
GPI 15715
ICU
Sedation
Additional relevant MeSH terms:
Layout table for MeSH terms
Fospropofol
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs